Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography

An Update for the U.S. Preventive Services Task Force

Linda Humphrey, Steven Teutsch, Mark Johnson

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Background: Lung cancer is the leading cause of cancer-related death in the United States and worldwide. No major professional organizations, including the U.S. Preventive Services Task Force (USPSTF), currently recommend screening for lung cancer. Purpose: To examine the evidence evaluating screening for lung cancer with chest radiography, sputum cytologic examination, and low-dose computed tomography (CT) to aid the USPSTF in updating its recommendation on lung cancer screening. Data Sources: MEDLINE, the Cochrane Library, reviews, editorials, and experts. Study Selection: Studies that evaluated mass screening programs for lung cancer involving the tests of interest were selected. All studies were reviewed, but only studies with control groups were rated in quality since these would most directly influence the USPSTF screening recommendation. Data Extraction: Data were abstracted to data collection forms. Studies were graded according to criteria developed by the USPSTF. Data Synthesis: None of the 6 randomized trials of screening for lung cancer with chest radiography alone or in combination with sputum cytologic examination showed benefit among those screened. All studies were limited because some level of screening occurred in the control population. Five case-control studies from Japan suggested benefit to both high- and low-risk men and women. All studies were limited by potential healthy screenee bias. Six cohort studies showed that when CT was used to screen for lung cancer, lung cancer was diagnosed at an earlier stage than in usual clinical care. However, these studies did not have control groups, making mortality evaluation difficult. In addition, the studies demonstrated a high rate of false-positive findings. Conclusions: Current data do not support screening for lung cancer with any method. These data, however, are also insufficient to conclude that screening does not work, particularly in women. Two randomized trials of screening with chest radiography or low-dose CT are currently under way and will better inform lung cancer screening decisions.

Original languageEnglish (US)
JournalAnnals of Internal Medicine
Volume140
Issue number9
StatePublished - May 4 2004
Externally publishedYes

Fingerprint

Advisory Committees
Sputum
Early Detection of Cancer
Radiography
Lung Neoplasms
Thorax
Tomography
Control Groups
Mass Screening
Information Storage and Retrieval
MEDLINE
Libraries
Case-Control Studies
Japan
Cohort Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{c269eac601754c589e468e7b7f8a383c,
title = "Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: An Update for the U.S. Preventive Services Task Force",
abstract = "Background: Lung cancer is the leading cause of cancer-related death in the United States and worldwide. No major professional organizations, including the U.S. Preventive Services Task Force (USPSTF), currently recommend screening for lung cancer. Purpose: To examine the evidence evaluating screening for lung cancer with chest radiography, sputum cytologic examination, and low-dose computed tomography (CT) to aid the USPSTF in updating its recommendation on lung cancer screening. Data Sources: MEDLINE, the Cochrane Library, reviews, editorials, and experts. Study Selection: Studies that evaluated mass screening programs for lung cancer involving the tests of interest were selected. All studies were reviewed, but only studies with control groups were rated in quality since these would most directly influence the USPSTF screening recommendation. Data Extraction: Data were abstracted to data collection forms. Studies were graded according to criteria developed by the USPSTF. Data Synthesis: None of the 6 randomized trials of screening for lung cancer with chest radiography alone or in combination with sputum cytologic examination showed benefit among those screened. All studies were limited because some level of screening occurred in the control population. Five case-control studies from Japan suggested benefit to both high- and low-risk men and women. All studies were limited by potential healthy screenee bias. Six cohort studies showed that when CT was used to screen for lung cancer, lung cancer was diagnosed at an earlier stage than in usual clinical care. However, these studies did not have control groups, making mortality evaluation difficult. In addition, the studies demonstrated a high rate of false-positive findings. Conclusions: Current data do not support screening for lung cancer with any method. These data, however, are also insufficient to conclude that screening does not work, particularly in women. Two randomized trials of screening with chest radiography or low-dose CT are currently under way and will better inform lung cancer screening decisions.",
author = "Linda Humphrey and Steven Teutsch and Mark Johnson",
year = "2004",
month = "5",
day = "4",
language = "English (US)",
volume = "140",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "9",

}

TY - JOUR

T1 - Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography

T2 - An Update for the U.S. Preventive Services Task Force

AU - Humphrey, Linda

AU - Teutsch, Steven

AU - Johnson, Mark

PY - 2004/5/4

Y1 - 2004/5/4

N2 - Background: Lung cancer is the leading cause of cancer-related death in the United States and worldwide. No major professional organizations, including the U.S. Preventive Services Task Force (USPSTF), currently recommend screening for lung cancer. Purpose: To examine the evidence evaluating screening for lung cancer with chest radiography, sputum cytologic examination, and low-dose computed tomography (CT) to aid the USPSTF in updating its recommendation on lung cancer screening. Data Sources: MEDLINE, the Cochrane Library, reviews, editorials, and experts. Study Selection: Studies that evaluated mass screening programs for lung cancer involving the tests of interest were selected. All studies were reviewed, but only studies with control groups were rated in quality since these would most directly influence the USPSTF screening recommendation. Data Extraction: Data were abstracted to data collection forms. Studies were graded according to criteria developed by the USPSTF. Data Synthesis: None of the 6 randomized trials of screening for lung cancer with chest radiography alone or in combination with sputum cytologic examination showed benefit among those screened. All studies were limited because some level of screening occurred in the control population. Five case-control studies from Japan suggested benefit to both high- and low-risk men and women. All studies were limited by potential healthy screenee bias. Six cohort studies showed that when CT was used to screen for lung cancer, lung cancer was diagnosed at an earlier stage than in usual clinical care. However, these studies did not have control groups, making mortality evaluation difficult. In addition, the studies demonstrated a high rate of false-positive findings. Conclusions: Current data do not support screening for lung cancer with any method. These data, however, are also insufficient to conclude that screening does not work, particularly in women. Two randomized trials of screening with chest radiography or low-dose CT are currently under way and will better inform lung cancer screening decisions.

AB - Background: Lung cancer is the leading cause of cancer-related death in the United States and worldwide. No major professional organizations, including the U.S. Preventive Services Task Force (USPSTF), currently recommend screening for lung cancer. Purpose: To examine the evidence evaluating screening for lung cancer with chest radiography, sputum cytologic examination, and low-dose computed tomography (CT) to aid the USPSTF in updating its recommendation on lung cancer screening. Data Sources: MEDLINE, the Cochrane Library, reviews, editorials, and experts. Study Selection: Studies that evaluated mass screening programs for lung cancer involving the tests of interest were selected. All studies were reviewed, but only studies with control groups were rated in quality since these would most directly influence the USPSTF screening recommendation. Data Extraction: Data were abstracted to data collection forms. Studies were graded according to criteria developed by the USPSTF. Data Synthesis: None of the 6 randomized trials of screening for lung cancer with chest radiography alone or in combination with sputum cytologic examination showed benefit among those screened. All studies were limited because some level of screening occurred in the control population. Five case-control studies from Japan suggested benefit to both high- and low-risk men and women. All studies were limited by potential healthy screenee bias. Six cohort studies showed that when CT was used to screen for lung cancer, lung cancer was diagnosed at an earlier stage than in usual clinical care. However, these studies did not have control groups, making mortality evaluation difficult. In addition, the studies demonstrated a high rate of false-positive findings. Conclusions: Current data do not support screening for lung cancer with any method. These data, however, are also insufficient to conclude that screening does not work, particularly in women. Two randomized trials of screening with chest radiography or low-dose CT are currently under way and will better inform lung cancer screening decisions.

UR - http://www.scopus.com/inward/record.url?scp=2342565832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342565832&partnerID=8YFLogxK

M3 - Article

VL - 140

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 9

ER -